Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the Commissioner of Food and Drugs to grant Commissioner's National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy designation and directs the FDA and Drug Enforcement Administration to establish a pathway for patient access to psychedelic drugs, including ibogaine compounds, under the Right to Try Act. It directs the Secretary of Health and Human Services to allocate at least $50 million through the Advanced Research Projects Agency for Health to partner with state programs advancing psychedelic drugs for serious mental illness, directs HHS, FDA, and the Department of Veterans Affairs to collaborate on clinical trials and sign data-sharing memoranda, and directs the Attorney General, in consultation with HHS, to review Schedule I products that complete Phase 3 trials for potential rescheduling.

None.

No known legal challenges.